NICE limits access to cancer drugs, study confirms
pharmafile | November 10, 2010 | News story | Sales and Marketing | BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests.
The review, conducted by Bristol-Myers Squibb, produced its analysis from a list of NICE guidance published between 2007 to the end of 2009 using a health technology resource website.
The research showed that in 2007 one in three new drugs was fully recommended for all eligible patients, but that this dropped to just one in 10 by the end of 2009.
BMS’ associate director health economics Maximilian Lebmeier, who led the analysis, said: “The coalition government has stated their commitment to widening access to medicines and we fully support this.
“The Cancer Drugs Fund is a good interim initiative for cancer patients, but we would like to see wider reform of the HTA system to make it fairer for all patients and widen access to effective medicines.”
Ben Adams
Related Content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds






